论文部分内容阅读
目的探讨格列美脲片联合吡格列酮治疗2型糖尿病(T2DM)患者的临床效果。方法选择100例T2DM患者,其中50例仅予吡格列酮治疗为对照组,另50例予吡格列酮联合格列美脲治疗。观察两组的有效性和药物安全性。结果两组治疗后FPG、2h PG、Hb A1c水平均明显下降(P<0.05),治疗组2h PG、Hb A1c水平明显低于对照组(P<0.05)。治疗组临床疗效优于对照组,但比较无统计学差异(P>0.05)。两组均未见严重不良事件发生,不影响继续治疗。结论格列美脲片联合吡格列酮治疗T2DM安全有效。
Objective To investigate the clinical effect of glimepiride combined with pioglitazone in the treatment of type 2 diabetes mellitus (T2DM). Methods 100 patients with T2DM were selected, of which 50 patients were treated with pioglitazone only and the other 50 patients were treated with pioglitazone and glimepiride. The effectiveness and drug safety of the two groups were observed. Results The levels of FPG, 2h PG and Hb A1c were significantly decreased in both groups (P <0.05). The levels of PG and Hb A1c in the treatment group were significantly lower than those in the control group (P <0.05). The clinical efficacy of the treatment group was better than that of the control group, but there was no significant difference (P> 0.05). No serious adverse events occurred in both groups, which did not affect the further treatment. Conclusion Glimepiride tablets combined with pioglitazone in the treatment of T2DM is safe and effective.